Peptides for skin health
Skin is an organ that rebuilds itself constantly — collagen scaffolding, new cells, repair signals. These articles cover peptides for skin renewal and repair, like the copper peptide GHK-Cu, plus practical topics like hair shedding and what actually supports healthy skin from the inside.
The tone is evidence-first: what researchers have measured, and what's still unknown. Treatments mentioned here are compounded and prescription-only, with a licensed provider reviewing every request. Topical and injectable routes are different conversations, and the articles say which one the evidence covers.
20 articles on this topic
-
Ozempic Face: What Facial Changes Really Mean
Ozempic face means a face looking less full after weight loss. Small studies document changes, but they cannot settle whether the drug has a direct effect.
-
GHK-Cu Myths: 8 Claims Checked Against Evidence
GHK-Cu has real human research on skin and wounds. That doesn't establish that injections make people younger, regrow hair, or work like a cream.
-
GHK-Cu News: October 2026 Update
New skin studies add useful detail about GHK-Cu, while human injection benefits remain unsettled. FDA's ingredient review is still pending.
-
Who Discovered PT-141? It Began as a Tanning Drug
PT-141 began as an accident: a University of Arizona tanning peptide caused unexpected erections in its first volunteers. Here is how that clue became bremelanotide, and what happened to its gray-market sibling.
-
GHK-Cu for Hair Growth: What the Evidence Shows
The copper peptide is all over hair-care feeds. The research behind it is mostly mice and cells, plus one famous follicle study that tested a different molecule.
-
Who Discovered GHK-Cu? Loren Pickart, in 1973
Loren Pickart reported the peptide in human serum in 1973, its sequence followed in 1977 and its grip on copper in 1980. The history is well documented; the human evidence is much thinner.
-
Is GHK-Cu FDA Approved? No, Its Review Is Pending
GHK-Cu is not FDA-approved. Its compounding review separates non-injectable use from injections, and the next advisory meeting still has no specific date.
-
Tirzepatide Psoriasis Data Don’t Make It a Treatment
New 52-week data found better skin and joint outcomes when branded tirzepatide was added to Taltz in adults with psoriatic disease and obesity. That supports treating two linked conditions together—not using tirzepatide alone for psoriasis.
-
GHK-Cu Studies Find a Gap in Human Evidence
A new systematic review found only two randomized human GHK-Cu trials among 20 eligible studies, and both were topical. The injectable claims run well ahead of the clinical evidence.
-
Does Sermorelin Cause Hair Loss? Evidence Review
Current evidence does not identify hair loss as a sermorelin side effect. Growth hormone and IGF-1 affect follicles, but that biology cannot explain why one person starts shedding.
-
KPV Peptide Benefits: What the Evidence Shows
KPV's strongest benefit signals are lower inflammatory activity in cultured cells and mouse colitis models. No human trial has established a KPV benefit, dose, or safety profile.
-
KLOW Peptide Benefits: What Each Component Adds
KLOW brings four peptide research rationales into one compounded formulation. The evidence runs from cell studies to animal models, but no clinical trial has tested the finished blend.
-
GHK-Cu Dosage: How Prescribers Set the Amount
There is no validated human injection dose for GHK-Cu. Topical studies disclose several concentrations, while compounded injection amounts come from clinical practice and must be tied to the exact vial and the person being treated.
-
KLOW vs GLOW: What KPV Adds to the Blend
KLOW and GLOW share BPC-157, TB-500, and GHK-Cu; KLOW adds KPV, an inflammation-focused tripeptide backed by cell and mouse studies—not blend-level human trials.
-
GHK-Cu Side Effects: Topical vs Injectable
GHK-Cu side effects are usually mild with topical cosmetics, but injectable GHK-Cu has no long-term human safety data. Route is the difference that matters.
-
Does Semaglutide Cause Hair Loss?
In the pooled 68-week trials, hair loss was reported by 3% of adults on semaglutide 2.4 mg against 1% on placebo. Telogen effluvium after fast weight loss explains it better than any proven effect on the follicle.
-
Does Tirzepatide Cause Hair Loss?
In the pivotal 72-week obesity trials, hair loss was reported by about 3%–7% of tirzepatide groups versus about 1% with placebo. Weight-loss-related telogen effluvium is the leading explanation, but a direct drug effect has not been ruled out.
-
Inside the Glow Peptide Blend
Glow combines three peptides with different, partly overlapping proposed jobs — BPC-157 signals new blood-vessel growth, TB-500 binds the cell-scaffolding protein actin, and GHK-Cu delivers copper to the enzyme that cross-links collagen.
-
Melanotan 2 Side Effects Beyond the Tan
Melanotan II's prospective human trial record is small; broader safety information comes mainly from case reports and seized vials.
-
GHK-Cu Benefits: The Copper Peptide, Explained
GHK-Cu benefits start from one well-documented fact: blood levels of the three-amino-acid peptide GHK fall from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60.